Brief: Kairos Pharma Announces Signing Of Term Sheet For Strategic Asset Acquisition
Brief: Kairos Pharma To Present Positive Safety And Efficacy Data From Phase 2 Prostate Cancer Trial At Esmo 2025
Brief: Kairos Pharma Reports Positive Interim Phase 2 Data For ENV105 In Advanced Prostate Cancer, PFS Over One Year
Brief: Kairos Pharma Announces Virtual KOL Event To Provide Perspectives On ENV105 Interim Efficacy Results In Advanced Prostate Cancer
Kairos Pharma jumps on prostate cancer trial data
Brief: Kairos Pharma Announces Positive Safety Results From Phase 2 Trial Of ENV-105 In Advanced Prostate Cancer
Brief: Kairos Pharma Remains Financially Strong Despite Recent Economic Headwinds
Brief: Kairos Pharma Announces Department Of Defense Grant To Support Its Study Of Lead Compound Env105 To Prevent Drug Resistance In Lung Cancer
Brief: Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer
Brief: Kairos Pharma Adds Huntsman Cancer Institute For Phase 2 ENV105 Clinical Trial
Brief: Kairos Pharma Ltd Announced Its Approval To Dual List Its Shares On Upstream
Brief: Kairos Pharma Enters Agreement with PreCheck Health Services
Brief: Kairos Pharma Prices $6.2 Million Initial Public Offering